Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Avicena(R) Appoints Dr. Uri Sagman to Board of Directors

Avicena(R) Group, Inc. (OTC Bulletin Board: AVGO), a late stage biotechnology company focused
on commercializing its proprietary cellular energy modulation technology, announced today the appointment of Uri Sagman, M.D, FRCPC, to the Company's Board of Directors. This appointment expands the Board to a total of 6 members.

Avicena(R) Appoints Dr. Uri Sagman to Board of Directors

PALO ALTO, CA | Posted on February 13th, 2007

"Dr. Sagman is an experienced entrepreneur and respected researcher
with a breadth of both business and scientific research experience. We
welcome Dr. Sagman and look forward to his contributions to the Avicena
board," stated Belinda Tsao-Nivaggioli, Avicena's chief executive officer.
"With an extensive background in guiding growth companies, Dr. Sagman will
assist Avicena in formulating and executing on value creation strategies."

Dr. Sagman has co-founded several companies including C Sixty, Inc., a
Canadian nanomedicine company focused on the development of fullerene
antioxidants for the treatment of Parkinson's disease, Alzheimer's disease
as well as certain skin conditions related to aging and UV exposure. Dr.
Sagman is also founder and chairman of GRN Capital Inc., a financial
services corporation with merchant banking and investment banking
operations based in Toronto. Separately, Dr. Sagman serves as Chairman of
GRN Health International Inc., a globally-based academic research
organization dedicated to medical research.

Dr. Sagman is also co-founder and Executive Director of the Canadian
NanoBusiness Alliance, a business association dedicated to the promotion of
Canadian nanotechnology overseas. In addition to his role with the Canadian
NanoBusiness Alliance, Dr. Sagman is also involved in the strategic
development of the National Nanotechnology Initiative Program.

Dr. Sagman studied at the McGill University, The University of Calgary,
The University of Toronto and Oxford University. Dr. Sagman has received
numerous awards and citations including the Young Investigator awards of
the American Society of Clinical Oncology (ASCO) and the American
Association for Cancer Research (AACR). Dr. Sagman is trained as a medical
oncologist and is a fellow of the Royal College of Physicians and Surgeons
of Canada. He is a fellowship recipient of the Medical Research Council of


About Avicena(R)
Avicena Group, Inc. (OTC Bulletin Board: AVGO) is a late stage
biotechnology company focused on developing products based on its
proprietary understanding of the regulation of cellular energy processes.
The company's core technologies, supported by a robust IP portfolio, have
broad applications in both pharmaceuticals and dermaceuticals. Avicena's
pharmaceutical program centers on rare neurological disorders (orphan
diseases). The company is currently analyzing data from its Phase IIb/III
trial in ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). Near
term, Avicena intends to initiate both a Phase III trial in Huntington's
disease and a Phase III trial in Parkinson's disease. Avicena's science is
well established and its products are safe and well tolerated. Unlike
traditional biotechnology companies, Avicena's clinical programs are
largely funded by government and non-profit organizations. Avicena
presently derives revenue from the sale of proprietary ingredients to skin
care manufacturers.


This release may contain forward-looking statements within the meaning
of the federal securities laws. Such forward-looking statements reflect,
among other things, management's current expectations, plans and
strategies, and anticipated financial results, all of which are subject to
known and unknown risks, uncertainties and factors that may cause our
actual results to differ materially from those expressed or implied by
these forward-looking statements. Many of these risks are beyond our
ability to control or predict. See "Risk Factors" in the company's
prospectus for a discussion of such risks, including the company's need for
additional funds, the company's dependence on a limited number of
therapeutic compounds, the early state of the products the company is
developing, uncertainties relating to clinical trials and regulatory
reviews, competition and dependence on collaborative partners, the
company's ability to avoid infringement of the patent rights of others, and
the company's ability to obtain adequate patent protection and to enforce
these rights. Because of these risks, uncertainties and assumptions, you
should not place undue reliance on these forward-looking statements.
Furthermore, forward-looking statements speak only as of the date they are
made. Avicena does not undertake any obligation to update or review any
such forward-looking information, whether as a result of new information,
future events or otherwise.

For more information, please click here

The Ruth Group (on behalf of Avicena(R) Group)
Sara Ephraim / John Quirk (investors)
(646) 536-7002 / 7029

Janine McCargo (media)
(646) 536-7033

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Rice U. refines filters for greener natural gas: New study defines best materials for carbon capture, methane selectivity March 23rd, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project